These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30054137)

  • 1. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival.
    Samson P; Puri V; Lockhart AC; Robinson C; Broderick S; Patterson GA; Meyers B; Crabtree T
    J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1725-1735. PubMed ID: 30054137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
    Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
    J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.
    Semenkovich TR; Panni RZ; Hudson JL; Thomas T; Elmore LC; Chang SH; Meyers BF; Kozower BD; Puri V
    J Thorac Cardiovasc Surg; 2018 May; 155(5):2221-2230.e1. PubMed ID: 29428700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Therapy for Node-Positive Esophageal Cancer After Induction and Surgery: A Multisite Study.
    Semenkovich TR; Subramanian M; Yan Y; Hofstetter WL; Correa AM; Cassivi SD; Inra ML; Stiles BM; Altorki NK; Chang AC; Brescia AA; Darling GE; Allison F; Broderick SR; Etchill EW; Fernandez FG; Chihara RK; Litle VR; Muñoz-Largacha JA; Kozower BD; Puri V; Meyers BF
    Ann Thorac Surg; 2019 Sep; 108(3):828-836. PubMed ID: 31229485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
    Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Therapy for Positive Nodes After Induction Therapy and Resection of Esophageal Cancer.
    Brescia AA; Broderick SR; Crabtree TD; Puri V; Musick JF; Bell JM; Kreisel D; Krupnick AS; Patterson GA; Meyers BF
    Ann Thorac Surg; 2016 Jan; 101(1):200-8; discussion 208-10. PubMed ID: 26507424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
    Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
    Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy.
    Samson P; Puri V; Broderick S; Patterson GA; Meyers B; Crabtree T
    Ann Thorac Surg; 2017 Feb; 103(2):406-415. PubMed ID: 28024648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma.
    Levinsky NC; Wima K; Morris MC; Ahmad SA; Shah SA; Starnes SL; Van Haren RM;
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2555-2566. PubMed ID: 31767364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy.
    Samson P; Puri V; Robinson C; Lockhart C; Carpenter D; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    Ann Thorac Surg; 2016 Jun; 101(6):2102-11. PubMed ID: 27083246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy.
    Giugliano DN; Berger AC; Pucci MJ; Rosato EL; Evans NR; Meidl H; Lamb C; Levine D; Palazzo F
    J Gastrointest Surg; 2017 Sep; 21(9):1377-1384. PubMed ID: 28664255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival.
    Lutfi W; Martinez-Meehan D; Dhupar R; Christie N; Sarkaria I; Ekeke C; Baker N; Luketich JD; Okusanya OT
    J Surg Oncol; 2020 Mar; 121(4):654-661. PubMed ID: 31970776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.
    Phillips AW; Lagarde SM; Navidi M; Disep B; Griffin SM
    Ann Surg; 2017 Apr; 265(4):750-756. PubMed ID: 27467444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base.
    Haque W; Verma V; Bernicker E; Butler EB; Teh BS
    Acta Oncol; 2018 Jun; 57(6):782-789. PubMed ID: 29188742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 3-Hole Minimally Invasive Esophagectomy: A Safe Procedure Following Neoadjuvant Chemotherapy and Radiation.
    Spector R; Zheng Y; Yeap BY; Wee JO; Lebenthal A; Swanson SJ; Marchosky DE; Enzinger PC; Mamon HJ; Lerut A; Odze R; Srivastava A; Agoston AT; Tippayawang M; Bueno R;
    Semin Thorac Cardiovasc Surg; 2015; 27(2):205-15. PubMed ID: 26686448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer.
    Wang J; Suri JS; Allen PK; Liao Z; Komaki R; Ho L; Hofstetter WL; Lin SH
    Am J Clin Oncol; 2016 Jun; 39(3):228-35. PubMed ID: 24710122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.